INTRODUCTION: Colorectal cancer (CRC) is the second leading cause of cancer-related deaths, but currently available noninvasive screening programs have achieved only a modest decrease in mortality. MicroRNAs (miRNA) play an important role in a wide array of biological processes and are commonly dysregulated in neoplasia. We aimed to evaluate the feasibility of fecal miRNAs as biomarkers for colorectal neoplasia screening. MATERIALS AND METHODS: Total RNA was extracted from freshly collected stool samples from 8 healthy volunteers and 29 samples collected via fecal occult blood testing from subjects with normal colonoscopies, colon adenomas, and CRCs. miRNA expression analyses were done with TaqMan quantitative reverse transcription-PCR for a subset of miRNAs. Illumina miRNA microarray profiling was done to evaluate the differences in expression patterns between normal colonic mucosa tissues and stool samples from healthy subjects. RESULTS: We efficiently extracted miRNAs from stool specimens using our developed protocol. Data from independent experiments showed high reproducibility for miRNA extraction and expression. miRNA expression patterns were similar in stool specimens among healthy volunteers, and reproducible in stool samples that were collected serially in time from the same individuals. miRNA expression profiles from 29 patients showed higher expression of miR-21 and miR-106a in patients with adenomas and CRCs compared with individuals free of colorectal neoplasia. CONCLUSION: Our data indicate that miRNAs could be extracted from stool easily and reproducibly. The stools of patients with colorectal neoplasms have unique and identifiable patterns of miRNA expression. IMPACT: Fecal miRNAs may be an excellent candidate for the development of a noninvasive screening test for colorectal neoplasms.
INTRODUCTION:Colorectal cancer (CRC) is the second leading cause of cancer-related deaths, but currently available noninvasive screening programs have achieved only a modest decrease in mortality. MicroRNAs (miRNA) play an important role in a wide array of biological processes and are commonly dysregulated in neoplasia. We aimed to evaluate the feasibility of fecal miRNAs as biomarkers for colorectal neoplasia screening. MATERIALS AND METHODS: Total RNA was extracted from freshly collected stool samples from 8 healthy volunteers and 29 samples collected via fecal occult blood testing from subjects with normal colonoscopies, colon adenomas, and CRCs. miRNA expression analyses were done with TaqMan quantitative reverse transcription-PCR for a subset of miRNAs. Illumina miRNA microarray profiling was done to evaluate the differences in expression patterns between normal colonic mucosa tissues and stool samples from healthy subjects. RESULTS: We efficiently extracted miRNAs from stool specimens using our developed protocol. Data from independent experiments showed high reproducibility for miRNA extraction and expression. miRNA expression patterns were similar in stool specimens among healthy volunteers, and reproducible in stool samples that were collected serially in time from the same individuals. miRNA expression profiles from 29 patients showed higher expression of miR-21 and miR-106a in patients with adenomas and CRCs compared with individuals free of colorectal neoplasia. CONCLUSION: Our data indicate that miRNAs could be extracted from stool easily and reproducibly. The stools of patients with colorectal neoplasms have unique and identifiable patterns of miRNA expression. IMPACT: Fecal miRNAs may be an excellent candidate for the development of a noninvasive screening test for colorectal neoplasms.
Authors: Angela B Y Hui; Wei Shi; Paul C Boutros; Naomi Miller; Melania Pintilie; Tony Fyles; David McCready; Derek Wong; Kate Gerster; Levi Waldron; Igor Jurisica; Linda Z Penn; Fei-Fei Liu Journal: Lab Invest Date: 2009-03-16 Impact factor: 5.662
Authors: Patrick S Mitchell; Rachael K Parkin; Evan M Kroh; Brian R Fritz; Stacia K Wyman; Era L Pogosova-Agadjanyan; Amelia Peterson; Jennifer Noteboom; Kathy C O'Briant; April Allen; Daniel W Lin; Nicole Urban; Charles W Drescher; Beatrice S Knudsen; Derek L Stirewalt; Robert Gentleman; Robert L Vessella; Peter S Nelson; Daniel B Martin; Muneesh Tewari Journal: Proc Natl Acad Sci U S A Date: 2008-07-28 Impact factor: 11.205
Authors: A Graser; P Stieber; D Nagel; C Schäfer; D Horst; C R Becker; K Nikolaou; A Lottes; S Geisbüsch; H Kramer; A C Wagner; H Diepolder; J Schirra; H J Roth; D Seidel; B Göke; M F Reiser; F T Kolligs Journal: Gut Date: 2008-10-13 Impact factor: 23.059
Authors: Bernard Levin; David A Lieberman; Beth McFarland; Kimberly S Andrews; Durado Brooks; John Bond; Chiranjeev Dash; Francis M Giardiello; Seth Glick; David Johnson; C Daniel Johnson; Theodore R Levin; Perry J Pickhardt; Douglas K Rex; Robert A Smith; Alan Thorson; Sidney J Winawer Journal: Gastroenterology Date: 2008-02-08 Impact factor: 22.682
Authors: Aaron J Schetter; Suet Yi Leung; Jane J Sohn; Krista A Zanetti; Elise D Bowman; Nozomu Yanaihara; Siu Tsan Yuen; Tsun Leung Chan; Dora L W Kwong; Gordon K H Au; Chang-Gong Liu; George A Calin; Carlo M Croce; Curtis C Harris Journal: JAMA Date: 2008-01-30 Impact factor: 56.272
Authors: Hongzhi Zou; William R Taylor; Jonathan J Harrington; Fareeda Taher Nazer Hussain; Xiaoming Cao; Charles L Loprinzi; Theodore R Levine; Douglas K Rex; Dennis Ahnen; Kandice L Knigge; Peter Lance; Xuan Jiang; David I Smith; David A Ahlquist Journal: Gastroenterology Date: 2008-10-15 Impact factor: 22.682
Authors: Melissa Piper Hunter; Noura Ismail; Xiaoli Zhang; Baltazar D Aguda; Eun Joo Lee; Lianbo Yu; Tao Xiao; Jeffrey Schafer; Mei-Ling Ting Lee; Thomas D Schmittgen; S Patrick Nana-Sinkam; David Jarjoura; Clay B Marsh Journal: PLoS One Date: 2008-11-11 Impact factor: 3.240
Authors: Francesco Bellissimo; Marilia Rita Pinzone; Bruno Cacopardo; Giuseppe Nunnari Journal: World J Gastroenterol Date: 2015-11-14 Impact factor: 5.742